Update information

Update information

November 2021: We reviewed the evidence on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease. We made new recommendations, and removed the original recommendation 1.6.7 from this guideline. See the new recommendations on chronic kidney disease in the NICE guideline on type 2 diabetes in adults. We also clarified the use of the term 'male' in the 4-variable Kidney Failure Risk Equation.

August 2021: This guideline is an update of NICE guideline CG182 (published July 2014), NICE guideline CG157 (published March 2013) and NICE guideline NG8 (published June 2015) and will replace them.

We have reviewed the evidence and made new recommendations on the assessment and management of CKD, management of hyperphosphataemia in people with CKD and the management of anaemia for people with CKD. These recommendations are marked [2021].

We have also made some changes without an evidence review:

  • We have updated some wording to bring the language and style up to date, without changing the meaning.

  • We have updated some recommendations to bring them in line with current terminology and practice.

  • We have combined, clarified or reworded some recommendations to make them clearer and to improve ease of reading.

In recommendations ending [2006], [2006, amended 2011], [2006, amended 2015], [2008], [2008, amended 2014], or [2014], we have not reviewed the evidence. In some cases minor changes have been made – for example, to update links, or bring the language and style up to date – without changing the intent of the recommendation.

Minor changes after publication

November 2023: We added a link to NICE's guideline on hypertension to recommendation 1.6.4.

November 2022: We added a link to our technology appraisal guidance on treating people with anaemia and chronic kidney disease.

March 2022: In the section on pharmacotherapy for CKD in adults, children, and young people with related persistent proteinuria, we added a cross-reference to NICE technology appraisal guidance on dapagliflozin for adults with CKD, with or without type 2 diabetes.

ISBN: 978-1-4731-4233-6

  • National Institute for Health and Care Excellence (NICE)